Immuron

Analyst Reports

Corporate Governance

Corporate Directory

Corporate

Capital Structure & Register

Annual Reports

Investor Presentations

NASDAQ

Investors

Company Media

Announcements

The Digest

Why Immuron?

Home

Plus Jakarta Sans

Click here to read full article

In May 2023, Immuron Limited announced it would present at the 13th Annual LD Micro Invitational (June 6–8, 2023, in California), where CEO Steven Lydeamore is scheduled to lead a presentation on June 6. The company is expected to showcase progress across its clinical pipeline—including oral polyclonal antibody therapies aimed at combating moderate to severe Campylobacteriosis, Clostridioides difficile infections, ETEC infections, and traveler’s diarrhea—as well as commercial performance for Travelan® across Australia, Canada, and the U.S.

NewsFile: Immuron Limited Announces Participation in the LD Micro Invitational XIII